DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells

Cancer Letters

Volumn 316, Issue 1, 2012, Pages 62-69

  Singh, Kamaleshwar P ^a   Treas, Justin ^a   Tyagi, Tulika ^a   Gao, Weimin ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell survival; DNA methylation; DNA repair; Epigenetics; Estrogen

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTRADIOL; ESTROGEN RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DRUG EXPOSURE; DRUG MECHANISM; ERCC1 GENE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCATION; HORMONE ACTION; HUMAN; HUMAN CELL; MISMATCH REPAIR; MLH1 GENE; MONOTHERAPY; MSH4 GENE; OGG1 GENE; ONCOGENE; PRIORITY JOURNAL; XPC GENE;

APOPTOSIS; AZACITIDINE; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR; DRUG INTERACTIONS; EPIGENESIS, GENETIC; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC;

EID: 84855354318     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.022     Document Type: Article

References (55)

1. Roy D., Singh K.P. Estrogen-induced genetic alterations and their role in carcinogenicity. Curr. Genomics 2004, 5:245-257.
2. IARC working group, Monographs on the evaluation of hormonal contraception and postmenopausal hormonal therapy. IARC Monographs 72 (1999) 399-530.
3. Li J.J., Papa D., Davis M.F., Weroha S.J., Aldaz C.M., El-Bayoumy K., Ballenger J., Tawfik O., Li S.A. Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol. Carcinog. 2002, 33:56-65.
4. Lippman M.E., Dickson R.B. Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog. Horm. Res. 1989, 45:383-435.
5. Platet N., Cathiard A.M., Gleizes M., Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit. Rev. Oncol. Hematol. 2004, 51:55-67.
6. Patel R.K., Trivedi A.H., Arora D.C., Bhatavdekar J.M., Patel D.D. DNA repair proficiency in breast cancer patients and their first-degree relatives. Int. J. Cancer 1997, 73:20-24.
7. Munot K., Bell S.M., Lane S., Horgan K., Hanby A.M., Speirs V. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Human Pathol. 2006, 37:989-999.
8. Murata H., Khattar N.H., Kang Y., Gu L., Li G.M. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene 2002, 21:5696-56703.
9. Yan Z.J., Roy D. Mutations of DNA polymerase beta mRNA in stilbene estrogen-induced kidney tumors. Biochem. Mol. Biol. Int. 1995, 37:175-183.
10. Murata H., Khattar N.H., Gu L., Li G.M. Role of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005, 223:143-150.
11. Fernandez S.V., Russo I.H., Russo J. Estradiol and its metabolite 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int. J. Cancer 2006, 118:1862-1868.
12. Hodgson A.V., Ayala-Torres S., Thompson E.B., Liehr J.G. Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis 1998, 19:2169-2172.
13. Singh K.P., Lopez-Guerrero J.A., Llombart-Bosch A., Roy D. Age, sex and co-exposure to N-ethyl-N-nitrosourea influence mutations in the Alu repeat sequences in diethylstilbestrol-induced kidney tumors in Syrian hamsters. Mutagenesis 2004, 19:67-73.
14. Singh K.P., Roy D. Allelic loss and mutations in a new ETRG-1 gene are early events in diethylstilbestrol-induced renal carcinogenesis in Syrian hamsters. Gene 2008, 408:18-26.
15. Momparler R.L., Bovenzi V., NA D. DNA methylation and cancer. J. Cell. Physiol. 2000, 183:145-154.
16. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genetics 2002, 3:415-428.
17. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M., Stephen B.B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 1994, 91:9700-9704.
18. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
19. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57:808-811.
20. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Willson J.K., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
21. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
22. 6 methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001, 61:4689-4692.
23. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 2001, 8:1076-1092.
24. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004, 10:20-26.
25. Kutanzi K.R., Koturbash I., Kovalchuk O. Reversibility of pre-malignant estrogen-induced epigenetic changes. Cell Cycle 2010, 9:3078-3084.
26. Wu Y., Alvarez M., Slamon D.J., Koeffler P., Vadgama J.V. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer 2010, 10:32.
27. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin. Oncol. 2005, 32:443-451.
28. Kagey J.D., Kapoor-Vazirani P., McCabe M.T., Powell D.R., Vertino P.M. Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol. Cancer Res. 2010, 8:1048-1059.
29. M. Al-Salihi, M. Yu, D.M. Burnett, A. Alexander, W.E. Samlowski, F.A. Fitzpatrick, The depletion of DNA Methyltransferase-1 and the epigenetic effects of 5-Aza-2'Deoxycytidine (Decitabine) are differentially regulated by cell cycle progression. Epigenetics 6 (2011) Epub ahead of print.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-delta delta Ct. Methods 2001, 25:402-408.
31. Arapshian A., Kuppumbatti Y.S., Mira-Y-Lopez R. Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 2000, 19:4066-4070.
32. Stefanska B., Rudnika K., Fabianowska A., Majewska K. Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. Eur. J. Pharmacol. 2010, 638:47-53.
33. Mongan N.P., Gudas L.J. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR beta 2 in breast cancer cells. Mol. Cancer Ther. 2005, 4:477-486.
34. DuMond J.W., Roy D. The inhibition of DNA repair capacity by stilbene estrogen in Leydig cells: its implications in the induction of instability in the testicular genome. Mutat. Res. 2001, 483:27-33.
35. Latimer J.J., Johnson J.M., Kelly C.M., Miles T.D., Beaudry-Rodgers K.A., Lalanne N.A., Vogel V.G., Kanbour-Shakir A., Kelley J.L., Johnson R.R., Grant S.G. Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc. Natl. Acad. Sci. USA 2010, 107:21725-21730.
36. Ming-Shiean H., Yu J.C., Wang H.W., Chen S.T., Hsiung C.N., Ding S.L., Wu P.E., Shen C.Y., Cheng C.W. Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk. Ann. Surg. Oncol. 2010, 17:760-771.
37. Pattarozzi A., Gatti M., Barbieri F., Würth R., Porcile C., Lunardi G., Ratto A., Favoni R., Bajetto A., Ferrari A., Florio T. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol. Pharmacol. 2008, 73:191-202.
38. Cejka P., Stojic L., Mojas N., Russell A.M., Heinimann K., Cannavó E., Pietro M.D., Marra G., Jiricny J. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J. 2003, 22:2245-2254.
39. Narine K.A., Keuling A.M., Gombos R., Tron V.A., Andrew S.E., Young L.C. Defining the DNA mismatch repair-dependent apoptotic pathway in primary cells: evidence for p53-independence and involvement of centrosomal caspase 2. DNA Repair (Amst) 2010, 9:161-168.
40. Martin L., Coffey M., Lawler M., Hollywood D., Marignol L. DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Lett. 2010, 291:142-149.
41. Naqvi R.A., Hussain A., Deo S.S., Kukreti H., Chauhan M., Sarin R., Saxena A., Asim M., Shukla N.K., Husain S.A., Pasha S.T., Basir S.F. Hypermethylation analysis of mismatch repair genes (hMLH1 and hMSH2) in locally advanced breast cancers in Indian women. Hum. Pathol. 2008, 39:672-680.
42. Murata H., Khattar N.H., Gu L., Li G.M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005, 223:143-150.
43. Chintamani, Jha B.P., Bhandari V., Bansal A., Saxena S., Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int. Semin. Surg. Oncol. 2007, 4:5.
44. Spagnoletti I., Pizzi C., Galietta A., Maio M.D., Mastranzo P., Daniele S., Limite G., Pettinato G., Contegiacomo A. Loss of hMSH2 expression in primary breast cancer with p53 alterations. Oncol. Rep. 2004, 11:845-851.
45. Bock N., Meden H., Regenbrecht M., Jünemann B., Wangerin J., Marx D. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. Anticancer Res. 2000, 20:119-124.
46. Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Chavez-Blanco A., Revilla-Vazquez A., Benitez-Bribiesca L., Duenas-González A. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med. 2006, 4:32.
47. Mirza S., Sharma G., Pandya P., Ralhan R. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol. Cell. Biochem. 2010, 342:101-109.
48. Dhénaut A., Boiteux S., Radicella J.P. Characterization of the hOGG1 promoter and its expression during the cell cycle. Mutat. Res. 2000, 461:109-118.
49. Van Engeland M., Weijenberg M.P., Roemen G.M., Brink M., de Bruïne A.P., Goldbohm R.A., vanden Brandt P.A., Baylin S.B., de Goeij A.F., Herman J.G. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003, 63:3133-3137.
50. Löf-Ohlin Z.M., Nilsson T.K. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. Oncol. Rep. 2009, 21:721-729.
51. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
52. Sanders S.L., Portoso M., Bahler J., Allshire R.C., Kouzarides T. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 2004, 119:603-614.
53. Esteller M., Almouzni G. How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond. EMBO Rep. 2005, 6:624-628.
54. Dobosy J.R., Selker E.U. Emerging connections between DNA methylation and histone acetylation. Cell. Mol. Life Sci. 2001, 58:721-727.
55. Espada J., Ballestar E., Fraga M.F., Villar-Garea A., Juarranz A., Stockert J.C., Robertson K.D., Fuks F., Esteller M. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J. Biol. Chem. 2004, 279:37175-37184.